Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -657.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $3M | $5M | $53M | $91M | — | — | — | — | — | — |
| Enterprise Value | $617031 | $-1270912 | $5M | $48M | $77M | — | — | — | — | — | — |
| P/E Ratio → | -0.11 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.14 | 0.67 | — | 17.52 | 6.81 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -657.2% | -657.2% | -4408.4% | -181.5% | -160.9% | -356.1% | -774.6% | -368.9% | -107.5% | — | — |
| ROA | -172.5% | -172.5% | -303.9% | -145.6% | -141.9% | -213.6% | -266.1% | -248.3% | -73.1% | -1927.5% | -226.9% |
| ROIC | — | — | — | — | — | -645.7% | -659.7% | -366.7% | -75.9% | -72044.7% | — |
| ROCE | -654.5% | -654.5% | -4404.0% | -181.4% | -160.4% | -349.4% | -777.1% | -380.0% | -103.6% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.17 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | — | -1.69 | -1.05 | -0.79 | -0.11 | -0.13 | -0.23 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -1267.44 | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -249.42 | -249.42 | -983.86 | -1930.92 | -264.81 | -31.18 | — | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.58 | 6.58 | 0.14 | 2.03 | 12.37 | 3.24 | 1.83 | 1.27 | 24.98 | 0.08 | 0.18 |
| Quick Ratio | 6.58 | 6.58 | 0.14 | 2.03 | 12.37 | 3.26 | 1.83 | 1.27 | 24.98 | 0.08 | 0.18 |
| Cash Ratio | 6.22 | 6.22 | 0.12 | 1.79 | 12.07 | 2.14 | 0.09 | 0.04 | 5.63 | 0.01 | 0.04 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $450799 | $75174 | $72236 | $65997 | $53815 | $52780 | $43587 | $33622 | $21334 | $0 |
Imminent liquidity and dilution
Based on reported figures, ALZN trades at a P/B ratio of 0.14, which suggests that the market assigns minimal value to the company's intellectual property relative to its historical book value, reflecting deep skepticism regarding the commercial viability of its current neurodegenerative pipeline and clinical trial progress.
The extremely low P/B multiple indicates that investors are pricing the company as a distressed asset rather than a growth-stage biotechnology firm. This valuation gap compared to peers like AC Immune suggests that the market may be discounting the potential of the AL001 cocrystal technology entirely due to the company's precarious cash position.
As reported in financial statements, the company's ROE of -67.1% in 2026Q3 highlights a severe inability to generate returns on invested capital, as the firm remains trapped in a cycle of funding R&D through equity dilution rather than internal value creation or operational efficiency.
The negative ROE trend is symptomatic of a business model that lacks a commercial engine to offset the high costs of clinical development. Investors should monitor whether management can achieve any clinical milestones that might justify the continued destruction of shareholder equity through ongoing capital raises.
According to recent SEC filings, the current ratio has fluctuated significantly, reaching 1.99 in 2026Q3, which masks the underlying reality that the company's cash reserves are rapidly depleting and may be insufficient to support the high-cost Phase II clinical trials without immediate and dilutive external financing.
While the current ratio appears superficially stable, the absolute level of cash and equivalents is insufficient for a company with such high R&D burn. The lack of access to traditional debt markets forces the company to rely on equity markets, which may lead to further value erosion for existing shareholders.
As indicated by the company's financial data, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for ALZN, as these metrics obscure the reality that the firm is a pre-revenue R&D entity where the primary driver of value is clinical trial success rather than current earnings.
Analysts often misapply earnings-based multiples to early-stage biotech, which leads to misleading conclusions about the company's valuation. Instead, investors should focus on the 'burn-to-cash' ratio and the probability-weighted net present value of the clinical pipeline to better understand the true risk-reward profile of the investment.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALZN stock.
Alzamend Neuro, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Alzamend Neuro, Inc.'s return on equity (ROE) is -657.2%. The historical average is -235.0%.
Based on historical data, Alzamend Neuro, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.